First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3; final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)

Maria Alsina1, Valentina Boni2, Aurelia de Vries Schultink3, Victor Moreno4, Kees Bol5, Martine Westendorp5, L. Andres Sirulnik5, Josep Tabernero1, and Emiliano Calvo2.1Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; 2START Madrid CIOCC, Hospital HM Universitario Sanchinarro, Madrid, Spain; 3Netherlands
Cancer Institute, Amsterdam, Netherlands; 4START – FJD, Madrid, Spain; 5Merus NV, Utrecht, Netherlands.

Poster presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, USA.